Incyte Corporation INCY on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing substantial ...

Hemab Therapeutics Inc. COAG on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease ...

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced interim clinical data from ...

DUBLIN--(BUSINESS WIRE)--The "Von Willebrand Disease (VWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts ...

The U.S. Food and Drug Administration has approved expanded use of Vonvendi (von Willebrand factor [recombinant]) for routine prophylactic use in adults with all types of the blood-clotting disorder ...

Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders. Learn ...

Like its namesake star twinkling 25 light-years from Earth, Vega Therapeutics hopes to shine as brightly in treating rare blood disorders, starting with a therapy for von Willebrand disease (VWD) that ...

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...

Incyte recently reported full Phase 1/2 multidose data for latarcibart (VGA039), an investigational, once‑monthly ...

Wilate becomes the only FDA-cleared VWF concentrate for routine prophylaxis across adults and children with all VWD types, including those younger than 6 years. WIL-33 studied severe early-onset VWD ...

Humate-P is a specialized medication known as a “complex” because it contains two essential proteins your body needs to form clots: antihemophilic factor (factor VIII) and von Willebrand factor (VWF).